Passage Common Stock vs Total Liab Analysis

PASG Stock

USD 0.62 0.11 21.57%

Passage Bio financial indicator trend analysis is much more than just breaking down Passage Bio prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Passage Bio is a good investment. Please check the relationship between Passage Bio Common Stock and its Total Liab accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.

Common Stock vs Total Liab

Common Stock vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Passage Bio Common Stock account and Total Liab. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Passage Bio's Common Stock and Total Liab is -0.35. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Total Liab in the same time period over historical financial statements of Passage Bio, assuming nothing else is changed. The correlation between historical values of Passage Bio's Common Stock and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Passage Bio are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Common Stock i.e., Passage Bio's Common Stock and Total Liab go up and down completely randomly.

Correlation Coefficient

-0.35

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Common Stock

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Passage Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Passage Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.The current Selling General Administrative is estimated to decrease to about 34.6 M. The current Issuance Of Capital Stock is estimated to decrease to about 142.5 K

	2021	2022	2023	2024 (projected)
Interest Expense	343K	2.3M	2.0M	2.0M
Depreciation And Amortization	1.5M	3.7M	3.7M	2.8M

Interest Expense Depreciation And Amortization

Passage Bio fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Net Working Capital	Common Stock	Property Plant Equipment
Total Assets		0.96	0.95	1.0	0.58	0.89	0.62	-0.56	-0.69	0.87	0.69	0.74	0.66	0.34	1.0	0.85	-0.92	0.11	0.88	-0.58	1.0	0.6	1.0	0.99	0.83	0.69
Other Current Liab	0.96		0.98	0.95	0.63	0.95	0.6	-0.49	-0.68	0.92	0.61	0.68	0.5	0.1	0.96	0.78	-0.83	0.14	0.86	-0.41	0.95	0.62	0.96	0.95	0.83	0.71
Total Current Liabilities	0.95	0.98		0.93	0.75	0.97	0.76	-0.36	-0.8	0.89	0.5	0.81	0.46	0.1	0.94	0.86	-0.8	0.0	0.94	-0.35	0.93	0.73	0.93	0.92	0.91	0.82
Total Stockholder Equity	1.0	0.95	0.93		0.54	0.86	0.59	-0.6	-0.67	0.85	0.73	0.72	0.7	0.4	1.0	0.85	-0.94	0.11	0.87	-0.64	1.0	0.57	1.0	0.99	0.82	0.66
Other Liab	0.58	0.63	0.75	0.54		0.73	0.89	0.28	-0.95	0.48	-0.11	0.85	-0.02	-0.21	0.52	0.79	-0.41	-0.52	0.83	0.07	0.54	0.97	0.52	0.49	0.85	0.98
Net Tangible Assets	0.89	0.95	0.97	0.86	0.73		0.72	-0.26	-0.78	0.85	0.39	0.74	0.3	-0.05	0.87	0.78	-0.7	0.05	0.91	-0.22	0.86	0.7	0.87	0.85	0.89	0.77
Property Plant And Equipment Net	0.62	0.6	0.76	0.59	0.89	0.72		0.15	-0.92	0.54	0.03	0.98	0.21	0.07	0.56	0.86	-0.47	-0.49	0.89	-0.05	0.59	0.84	0.55	0.53	0.9	0.92
Net Debt	-0.56	-0.49	-0.36	-0.6	0.28	-0.26	0.15		-0.13	-0.55	-0.98	-0.04	-0.86	-0.63	-0.61	-0.27	0.69	-0.46	-0.21	0.79	-0.6	0.2	-0.61	-0.63	-0.15	0.11
Retained Earnings	-0.69	-0.68	-0.8	-0.67	-0.95	-0.78	-0.92	-0.13		-0.48	-0.06	-0.91	-0.17	-0.03	-0.64	-0.9	0.59	0.53	-0.92	0.17	-0.67	-0.97	-0.63	-0.61	-0.94	-0.98
Accounts Payable	0.87	0.92	0.89	0.85	0.48	0.85	0.54	-0.55	-0.48		0.62	0.61	0.51	0.08	0.87	0.64	-0.67	0.31	0.73	-0.27	0.85	0.4	0.87	0.87	0.68	0.56
Cash	0.69	0.61	0.5	0.73	-0.11	0.39	0.03	-0.98	-0.06	0.62		0.23	0.92	0.69	0.73	0.45	-0.82	0.34	0.39	-0.86	0.73	-0.02	0.73	0.75	0.34	0.07
Non Current Assets Total	0.74	0.68	0.81	0.72	0.85	0.74	0.98	-0.04	-0.91	0.61	0.23		0.41	0.26	0.68	0.94	-0.63	-0.45	0.94	-0.26	0.72	0.83	0.67	0.65	0.93	0.91
Non Currrent Assets Other	0.66	0.5	0.46	0.7	-0.02	0.3	0.21	-0.86	-0.17	0.51	0.92	0.41		0.88	0.67	0.58	-0.82	0.09	0.46	-0.9	0.7	0.08	0.67	0.68	0.4	0.18
Other Assets	0.34	0.1	0.1	0.4	-0.21	-0.05	0.07	-0.63	-0.03	0.08	0.69	0.26	0.88		0.34	0.39	-0.6	-0.08	0.21	-0.87	0.4	-0.08	0.34	0.36	0.17	-0.03
Cash And Short Term Investments	1.0	0.96	0.94	1.0	0.52	0.87	0.56	-0.61	-0.64	0.87	0.73	0.68	0.67	0.34		0.81	-0.92	0.17	0.84	-0.6	1.0	0.55	1.0	1.0	0.79	0.64
Common Stock Shares Outstanding	0.85	0.78	0.86	0.85	0.79	0.78	0.86	-0.27	-0.9	0.64	0.45	0.94	0.58	0.39	0.81		-0.83	-0.42	0.96	-0.52	0.85	0.84	0.8	0.79	0.96	0.89
Non Current Liabilities Total	-0.92	-0.83	-0.8	-0.94	-0.41	-0.7	-0.47	0.69	0.59	-0.67	-0.82	-0.63	-0.82	-0.6	-0.92	-0.83		0.02	-0.78	0.84	-0.94	-0.52	-0.92	-0.93	-0.75	-0.57
Other Current Assets	0.11	0.14	0.0	0.11	-0.52	0.05	-0.49	-0.46	0.53	0.31	0.34	-0.45	0.09	-0.08	0.17	-0.42	0.02		-0.29	0.0	0.11	-0.61	0.19	0.2	-0.37	-0.51
Other Stockholder Equity	0.88	0.86	0.94	0.87	0.83	0.91	0.89	-0.21	-0.92	0.73	0.39	0.94	0.46	0.21	0.84	0.96	-0.78	-0.29		-0.38	0.87	0.84	0.84	0.82	0.99	0.9
Total Liab	-0.58	-0.41	-0.35	-0.64	0.07	-0.22	-0.05	0.79	0.17	-0.27	-0.86	-0.26	-0.9	-0.87	-0.6	-0.52	0.84	0.0	-0.38		-0.64	-0.11	-0.6	-0.62	-0.35	-0.12
Net Invested Capital	1.0	0.95	0.93	1.0	0.54	0.86	0.59	-0.6	-0.67	0.85	0.73	0.72	0.7	0.4	1.0	0.85	-0.94	0.11	0.87	-0.64		0.57	1.0	0.99	0.82	0.66
Property Plant And Equipment Gross	0.6	0.62	0.73	0.57	0.97	0.7	0.84	0.2	-0.97	0.4	-0.02	0.83	0.08	-0.08	0.55	0.84	-0.52	-0.61	0.84	-0.11	0.57		0.54	0.52	0.88	0.97
Total Current Assets	1.0	0.96	0.93	1.0	0.52	0.87	0.55	-0.61	-0.63	0.87	0.73	0.67	0.67	0.34	1.0	0.8	-0.92	0.19	0.84	-0.6	1.0	0.54		1.0	0.79	0.63
Net Working Capital	0.99	0.95	0.92	0.99	0.49	0.85	0.53	-0.63	-0.61	0.87	0.75	0.65	0.68	0.36	1.0	0.79	-0.93	0.2	0.82	-0.62	0.99	0.52	1.0		0.77	0.61
Common Stock	0.83	0.83	0.91	0.82	0.85	0.89	0.9	-0.15	-0.94	0.68	0.34	0.93	0.4	0.17	0.79	0.96	-0.75	-0.37	0.99	-0.35	0.82	0.88	0.79	0.77		0.92
Property Plant Equipment	0.69	0.71	0.82	0.66	0.98	0.77	0.92	0.11	-0.98	0.56	0.07	0.91	0.18	-0.03	0.64	0.89	-0.57	-0.51	0.9	-0.12	0.66	0.97	0.63	0.61	0.92

Click cells to compare fundamentals

Passage Bio Account Relationship Matchups

Passage Bio fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	178.6M	328.0M	355.1M	243.5M	150.5M	236.4M
Other Current Liab	3.1M	15.9M	20.1M	7.7M	8.3M	10.1M
Total Current Liabilities	3.7M	21.2M	29.5M	18.4M	16.3M	16.4M
Total Stockholder Equity	174.4M	304.7M	318.7M	201.4M	111.3M	201.3M
Net Tangible Assets	(56.3M)	304.7M	318.7M	201.4M	231.6M	166.4M
Property Plant And Equipment Net	1.1M	2.8M	23.8M	42.2M	32.2M	18.7M
Net Debt	(158.9M)	(135.0M)	(129.0M)	(7.5M)	4.6M	4.8M
Retained Earnings	(58.7M)	(170.9M)	(356.3M)	(492.4M)	(594.5M)	(564.7M)
Accounts Payable	629K	5.3M	9.4M	4.1M	1.3M	1.2M
Cash	158.9M	135.0M	129.0M	34.6M	21.7M	20.6M
Non Current Assets Total	12.8M	8.0M	30.0M	46.5M	32.6M	23.8M
Non Currrent Assets Other	11.8M	5.2M	6.2M	4.3M	433K	411.4K
Other Assets	11.8M	2.8M	0.0	4.3M	1.0	0.95
Cash And Short Term Investments	158.9M	304.8M	315.8M	189.6M	114.3M	203.2M
Common Stock Shares Outstanding	45.8M	38.6M	53.3M	54.4M	54.7M	49.7M
Liabilities And Stockholders Equity	178.6M	328.0M	355.1M	243.5M	150.5M	236.4M
Non Current Liabilities Total	580K	2.1M	6.9M	23.8M	22.9M	13.6M
Other Current Assets	6.9M	12.4M	9.3M	7.4M	3.7M	6.4M
Other Stockholder Equity	233.0M	475.6M	675.3M	694.7M	705.8M	510.6M
Total Liab	4.3M	23.3M	36.4M	42.2M	39.3M	35.0M
Net Invested Capital	174.4M	304.7M	318.7M	201.4M	111.3M	201.3M
Property Plant And Equipment Gross	1.1M	2.8M	23.8M	22.5M	39.4M	41.4M
Total Current Assets	165.8M	317.2M	325.1M	197.0M	118.0M	212.0M
Net Working Capital	162.1M	296.0M	295.6M	178.7M	101.6M	195.6M
Property Plant Equipment	1.1M	2.8M	23.8M	22.5M	25.9M	27.2M

Currently Active Assets on Macroaxis

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America
S	SentinelOne
WD	Walker Dunlop

When determining whether Passage Bio is a strong investment it is important to analyze Passage Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Passage Bio's future performance. For an informed investment choice regarding Passage Stock, refer to the following important reports:

How To Invest In Passage

Details

Is Passage Stock a good investment?

Details

What is Passage Bio's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.

You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.17)

Return On Assets

(0.34)

Return On Equity

(0.64)

The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Passage Common Stock vs Total Liab Analysis

Common Stock vs Total Liab

Common Stock vs Total Liab Correlation Analysis

Correlation Coefficient

Common Stock

Total Liab

Passage Bio fundamental ratios Correlations

Passage Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Passage Bio fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity

Property Plant Equipment	- 0.98	Retained Earnings
Cash	- 0.98	Net Debt
Property Plant And Equipment Gross	- 0.97	Retained Earnings
Retained Earnings	- 0.95	Other Liab
Net Invested Capital	- 0.94	Non Current Liabilities Total
Common Stock	- 0.94	Retained Earnings